Captopril kinetics in chronic congestive heart failure

Area of Science:

• Pharmacology
• Cardiology
• Clinical Therapeutics

Background:

• Congestive heart failure (CHF) is a complex condition requiring effective pharmacological management.
• Understanding the pharmacokinetic profile of drugs like captopril is crucial for optimizing treatment in CHF patients.
• Hormonal and hemodynamic alterations are key indicators of drug efficacy in cardiovascular diseases.

Purpose of the Study:

• To investigate the pharmacokinetics of oral captopril in patients with congestive heart failure.
• To correlate captopril's kinetic profile with observed hormonal and hemodynamic changes.
• To assess the impact of single-dose versus short-term therapy on captopril's effects.

Main Methods:

• Single oral dose (25 mg) and short-term therapy (25 mg t.i.d. for 3 days) of captopril administered to 12 CHF patients.
• Kinetic analysis of captopril, including time to maximum concentration (tmax) and half-life (t1/2) for free and total drug.
• Monitoring of hormonal (e.g., plasma renin activity - PRA) and hemodynamic parameters.
• Comparison of kinetic and pharmacodynamic data between day 1 and day 5 of treatment.

Main Results:

• Captopril kinetics in CHF patients showed a slightly higher tmax and shorter free t1/2 compared to normal subjects.
• Total captopril half-life was longer in CHF patients, suggesting potential accumulation.
• Urinary excretion of captopril was slower in CHF patients.
• Short-term therapy led to earlier tmax, shorter t1/2, higher blood levels, and increased urinary excretion by day 5.
• Significant hemodynamic improvement was observed after a single dose, correlating with baseline PRA.
• Onset of converting-enzyme inhibition, PRA changes, and hemodynamic improvements correlated with captopril blood levels.

Conclusions:

• Captopril exhibits altered pharmacokinetics in congestive heart failure patients, including potential for accumulation.
• The drug's hemodynamic and hormonal effects are closely linked to its blood concentrations and the degree of converting-enzyme inhibition.
• Captopril demonstrates therapeutic efficacy in improving hemodynamics in CHF, with effects modulated by baseline renin activity.